Two AIM-listed life science names advanced their pipeline positioning today, with intellectual property and infrastructure building rather than clinical readouts driving the news. ValiRx strengthened the patent estate underpinning its cancer subsidiary Cytolytix, while ImmuPharma continued assembling the contract research network needed to take Kapiglucagon into clinical trials.
ValiRx secures second European patent for Cytolytix platform
ValiRx (AIM:VAL), the cancer therapeutics and women's health specialist, said its majority-owned subsidiary Cytolytix has received notification of intention to grant a second European patent, building on the original peptide formulation patent granted in May covering "Nanoparticle for Anti-Cancer Peptides and Uses Thereof". The shares traded at 0.16p as the company set out how the two patent families now sit alongside each other to reinforce Cytolytix's intellectual property position ahead of ongoing licensing and partnership talks.
The notification follows a separate filing on 26 May for additional protection covering a second-generation delivery platform built on novel lipid formulations of ValiRx's oncolytic peptide. That filing includes data showing the platform induces immunogenic cell death in triple negative breast cancer cells, a mechanism that alerts the immune system to tumour presence. ValiRx said a further announcement will follow once the second patent is formally granted, with Inaphaea and partners ScreenIn3D, Voxcell and Bioreparia credited with advancing the platform's development.
"This is a significant milestone for Cytolytix, confirming the novelty of the platform and providing a solid base to build on with further IP developed in house," said Mark Eccleston, chief executive of ValiRx.
The immune-activating data matters beyond the patent office: it feeds directly into ValiRx's comparative oncology strategy, which tests therapies in pet patients with naturally occurring tumours alongside human trial participants with intact immune systems. A second granted patent, layered on the first, gives Cytolytix a broader defensive perimeter just as it seeks external partners, the kind of freedom-to-operate clarity that licensing counterparties typically demand before committing capital, even though the notice itself precedes formal grant and remains a procedural rather than commercial milestone.
ImmuPharma names Kymos Group as Kapiglucagon bioanalytical partner
Immupharma (AIM:IMM) has appointed Kymos Group as bioanalytical contract research organisation partner for its Kapiglucagon program following a competitive tender, with shares slipping 6.25% to 3.75p on the day. Kymos Germany/Prolytic, which is GLP-certified, GCP-compliant and FDA-inspected, will develop and validate regulated bioanalytical methods to analyse samples from both the nonclinical program and the planned Phase 1 clinical study.
The appointment follows ImmuPharma's recent selection of Thermo Fisher as chemistry, manufacturing and controls partner and Bachem as active pharmaceutical ingredient manufacturer for the same program, rounding out the development infrastructure before clinical work begins. "This appointment represents another important step in building the development infrastructure required to advance Kapiglucagon towards the clinic," said Dr Sébastien Goudreau. Kymos Group's own chief executive, also named Sébastien Goudreau, added that the CRO "brings relevant peptide bioanalysis expertise and the capabilities required to support the program through its nonclinical and early clinical development."
ImmuPharma is evaluating a 505(b)(2) regulatory pathway in the United States for Kapiglucagon, which would let it draw on existing data for native glucagon rather than file a full new drug application, subject to FDA confirmation. Assembling CMC, API and now bioanalytical partners in quick succession signals a company methodically de-risking the operational path to clinic, even as the share price move suggests the market is treating the appointment as routine execution rather than a fresh catalyst.
